热搜词：
注册
登录
CN
  • CN
  • EN

产品中心 药物靶点和Fc受体 药物靶点

所有图片（1/3）

OX40/TNFRSF4/CD134 Fc Chimera Protein, Human

TNFRSF4,OX40,CD134,OX40L receptor,ACT35,TXGP1L

价格 ￥2,200.00 （ 供应商现货 ： 3-5个工作日）
货号 UA011039
规格
数量
收藏 分享
产品介绍

产品介绍 评论(0)

产品规格

  • 物种

    Human

  • 分子别名

    TNFRSF4,OX40,CD134,OX40L receptor,ACT35,TXGP1L

  • Accession

    P43489

  • 表达序列

    Leu29-Ala21, with hIgG Fc

  • 表达宿主

    HEK293

  • 分子量

    65-75 kDa (Reducing)

  • 纯度

    ＞95% by SDS-PAGE & RP-HPLC

  • 活性

    Immobilized OX40/TNFRSF4/CD134 Fc Chimera Protein, Human (Cat. No. UA011039) at 2.0μg/mL (100μL/well) can bind Biotinylated Anti-Human OX40 (Ivuxolimab) with EC50 of 2.45-3.22 ng/mL.

  • 标记

    Unconjugated

  • 标签

    Human Fc Tag

  • 性状

    Lyophilized Powder

  • 缓冲体系

    PBS, PH7.4, 5% trehalose

  • 溶解方法

    Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.

  • 储存条件

    · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
    · 3 months, -20 to -80℃ under sterile conditions after reconstitution.
    · 1 week, 2 to 8℃ under sterile conditions after reconstitution.
    · Please avoid repeated freeze-thaw cycles.

  • 文献引用

    Budhu S, Kim K, Yip W, La Rosa S, Jebiwott S, Cai L, Holland A, Thomas J, Preise D, Somma A, Gordon B, Scherz A, Wolchok JD, Erinjeri J, Merghoub T, Coleman JA. Comparative study of immune response to local tumor destruction modalities in a murine breast cancer model. Front Oncol. 2024 Jun 18;14:1405486.

背景介绍

  • Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.The interaction between OX40 and OX40L plays an important role in antigen-specific T-cell expansion and survival. OX40 and OX40L also regulate cytokine production from T cells, antigen-presenting cells, natural killer cells, and natural killer T cells, and modulate cytokine receptor signaling. In line with these important modulatory functions, OX40-OX40L interactions have been found to play a central role in the development of multiple inflammatory and autoimmune diseases, making them attractive candidates for intervention in the clinic.Conversely, stimulating OX40 has shown it to be a candidate for therapeutic immunization strategies for cancer and infectious disease.

  • 电泳

  • 反相高效液相色谱(RP-HPLC)

  • ELISA

    • Immobilized OX40/TNFRSF4/CD134 Fc Chimera Protein, Human (Cat. No. UA011039) at 2.0μg/mL (100μL/well) can bind Biotinylated Anti-Human OX40 (Ivuxolimab) with EC50 of 2.45-3.22 ng/mL.

评论(0)